HUT65228A - Process for producing decahyroisoquinoline-3-carboxylic acid derivatives and pharmaceutical preparations containing them - Google Patents
Process for producing decahyroisoquinoline-3-carboxylic acid derivatives and pharmaceutical preparations containing themInfo
- Publication number
- HUT65228A HUT65228A HU9302453A HU9302453A HUT65228A HU T65228 A HUT65228 A HU T65228A HU 9302453 A HU9302453 A HU 9302453A HU 9302453 A HU9302453 A HU 9302453A HU T65228 A HUT65228 A HU T65228A
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- chr
- hydrogen
- chem
- phenyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- -1 hydroxy, amino, bromo, iodo Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical class C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 abstract 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/939,780 US5284957A (en) | 1992-09-03 | 1992-09-03 | Excitatory amino acid receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
HU9302453D0 HU9302453D0 (en) | 1993-11-29 |
HUT65228A true HUT65228A (en) | 1994-05-02 |
HU224015B1 HU224015B1 (hu) | 2005-04-28 |
Family
ID=25473721
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9302453A HU224015B1 (hu) | 1992-09-03 | 1993-08-30 | Eljárás dekahidro-izokinolin-3-karbonsavszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
HU95P/P00401P HU211992A9 (en) | 1992-09-03 | 1995-06-22 | Excitatory aminoacid receptor antagonists |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU95P/P00401P HU211992A9 (en) | 1992-09-03 | 1995-06-22 | Excitatory aminoacid receptor antagonists |
Country Status (27)
Country | Link |
---|---|
US (7) | US5284957A (hu) |
EP (1) | EP0590789B9 (hu) |
JP (1) | JP3601840B2 (hu) |
KR (1) | KR100274367B1 (hu) |
CN (1) | CN1043762C (hu) |
AT (1) | ATE234287T1 (hu) |
AU (1) | AU656482B2 (hu) |
BR (1) | BR9303495A (hu) |
CA (2) | CA2484248A1 (hu) |
CZ (1) | CZ285049B6 (hu) |
DE (1) | DE69332754T2 (hu) |
DK (1) | DK0590789T3 (hu) |
ES (1) | ES2194844T3 (hu) |
FI (1) | FI933810A (hu) |
HK (1) | HK1013989A1 (hu) |
HU (2) | HU224015B1 (hu) |
IL (1) | IL106809A (hu) |
MX (1) | MX9305294A (hu) |
MY (1) | MY131442A (hu) |
NO (1) | NO304072B1 (hu) |
NZ (1) | NZ248513A (hu) |
PH (1) | PH31250A (hu) |
PL (1) | PL173809B1 (hu) |
PT (1) | PT590789E (hu) |
RU (1) | RU2117661C1 (hu) |
SG (1) | SG45319A1 (hu) |
ZA (1) | ZA936231B (hu) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2087812B1 (es) * | 1993-07-02 | 1997-03-16 | Lilly Co Eli | Derivados de decahidroisoquinolina utiles como antagonistas de los receptrores de los aminoacidos excitadores. |
US5580877A (en) * | 1994-04-25 | 1996-12-03 | Merck Sharp & Dohme Ltd. | Pyrazolo-quinoline derivatives for treating cerebral ischemia |
US5446051A (en) * | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
US5723414A (en) * | 1996-01-24 | 1998-03-03 | Rohm And Haas Company | 5-aryl-isoxazolinones and herbicidal use thereof |
KR100375155B1 (ko) | 1996-05-15 | 2003-08-19 | 화이자 인코포레이티드 | 신규한2,3-이치환된-4(3에이치)-퀴나졸리논 |
ES2184960T3 (es) * | 1996-05-15 | 2003-04-16 | Pfizer | Nuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas. |
TR199902449T2 (xx) * | 1997-04-07 | 2000-07-21 | Eli Lilly And Company | Farmakolojik etkin maddeler. |
US6627755B1 (en) | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
US6323208B1 (en) | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
JP2002505288A (ja) | 1998-03-02 | 2002-02-19 | コセンシス,インコーポレイテッド | 置換キナゾリンおよびアナログならびにそれらの使用 |
DK1200073T3 (da) * | 1999-07-06 | 2007-05-07 | Lilly Co Eli | Selektive iGluR5-receptorantagonister til behandling af migræne |
AU5591900A (en) * | 1999-07-06 | 2001-01-22 | Eli Lilly And Company | Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid |
US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
EP1257545A1 (en) * | 1999-12-22 | 2002-11-20 | Eli Lilly And Company | SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS |
MXPA03005982A (es) * | 2001-01-05 | 2003-09-10 | Lilly Co Eli | Antagonistas de receptores de aminoacidos excitadores. |
US6924294B2 (en) | 2001-01-05 | 2005-08-02 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
AU2002227020A1 (en) | 2001-01-05 | 2002-07-16 | Eli Lilly And Company | Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists |
US7205313B2 (en) | 2001-01-05 | 2007-04-17 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
EP1351952A2 (en) | 2001-01-05 | 2003-10-15 | Eli Lilly And Company | Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists |
CN1484642A (zh) * | 2001-01-05 | 2004-03-24 | 兴奋性氨基酸受体拮抗剂 | |
GB0106858D0 (en) * | 2001-03-20 | 2001-05-09 | Perkins Engines Co Ltd | An accessory drive for driving an engine accessory |
GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
US7091249B2 (en) * | 2001-12-26 | 2006-08-15 | University Of Iowa Research Foundation | Drugs for spinal anesthesia |
WO2003082856A1 (en) * | 2002-03-22 | 2003-10-09 | Eli Lilly And Company | Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists |
PT1511741E (pt) | 2002-04-26 | 2013-02-05 | Lilly Co Eli | Derivados éster de um ácido deca-hidroisoquinolino-3- carboxílico como analgésicos |
US20050176068A1 (en) * | 2002-04-26 | 2005-08-11 | Emmert-Buck Michael R. | Direct cell target analysis |
GB0222056D0 (en) * | 2002-09-23 | 2002-10-30 | Novartis Ag | Process for the manufacture of organic compounds |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
US20060220794A1 (en) * | 2005-04-04 | 2006-10-05 | Jeffrey Zhu | Phase modulation for backscatter transponders |
US20070293573A1 (en) * | 2006-02-24 | 2007-12-20 | Eric Gouaux | Glu2 receptor modulators |
US20080108603A1 (en) * | 2006-10-19 | 2008-05-08 | Eisenach James C | Combination therapy for the treatment of pain |
US20080108622A1 (en) * | 2006-10-19 | 2008-05-08 | Eisenach James C | Combination therapy for the treatment of pain |
US20090270508A1 (en) * | 2007-02-23 | 2009-10-29 | James Eric Gouaux | GluR2 receptor modulators |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
CN101812031A (zh) * | 2010-04-29 | 2010-08-25 | 南通市华峰化工有限责任公司 | 一种5-羟烷基四氮唑的高压生产方法 |
EP2822931B1 (en) | 2012-03-09 | 2017-05-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
MX2015007433A (es) | 2012-12-20 | 2015-12-07 | Inception 2 Inc | Compuestos de triazolona y usos de los mismos. |
TWI593692B (zh) * | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
EA201690230A1 (ru) | 2013-09-06 | 2016-07-29 | Инсепшн 2, Инк. | Соединения триазолона и их применения |
KR20200035035A (ko) | 2017-07-31 | 2020-04-01 | 노파르티스 아게 | 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도 |
MX2022016223A (es) * | 2020-07-02 | 2023-02-23 | Sea Pharmaceuticals Llc | Composiciones farmaceuticas de acido 6-(2-(2h-tetrazol-5-il)etil)- 6-fluorodecahidroisoquinolina-3-carboxilico y derivados de ester del mismo. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK704488D0 (da) * | 1988-12-19 | 1988-12-19 | Novo Industri As | Nye n-substituerede azaheterocykliske carboxylsyrer |
US4897490A (en) * | 1987-02-25 | 1990-01-30 | Bristol-Meyers Company | Antihypercholesterolemic tetrazole compounds |
US4824959A (en) * | 1988-02-18 | 1989-04-25 | Bristol-Myers Company | Intermediates for antihypercholesterolemic tetrazole compounds |
US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5192751A (en) * | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
-
1992
- 1992-09-03 US US07/939,780 patent/US5284957A/en not_active Expired - Lifetime
-
1993
- 1993-08-25 DE DE69332754T patent/DE69332754T2/de not_active Expired - Lifetime
- 1993-08-25 SG SG1996003438A patent/SG45319A1/en unknown
- 1993-08-25 DK DK93306745T patent/DK0590789T3/da active
- 1993-08-25 ES ES93306745T patent/ES2194844T3/es not_active Expired - Lifetime
- 1993-08-25 PT PT93306745T patent/PT590789E/pt unknown
- 1993-08-25 ZA ZA936231A patent/ZA936231B/xx unknown
- 1993-08-25 CZ CZ931745A patent/CZ285049B6/cs not_active IP Right Cessation
- 1993-08-25 EP EP93306745A patent/EP0590789B9/en not_active Expired - Lifetime
- 1993-08-25 US US08/111,747 patent/US5399696A/en not_active Expired - Lifetime
- 1993-08-25 AT AT93306745T patent/ATE234287T1/de active
- 1993-08-26 CA CA002484248A patent/CA2484248A1/en not_active Abandoned
- 1993-08-26 BR BR9303495A patent/BR9303495A/pt not_active Application Discontinuation
- 1993-08-26 IL IL10680993A patent/IL106809A/en not_active IP Right Cessation
- 1993-08-26 CA CA002104909A patent/CA2104909C/en not_active Expired - Lifetime
- 1993-08-27 PH PH46762A patent/PH31250A/en unknown
- 1993-08-27 NZ NZ248513A patent/NZ248513A/en unknown
- 1993-08-30 HU HU9302453A patent/HU224015B1/hu active IP Right Grant
- 1993-08-31 FI FI933810A patent/FI933810A/fi unknown
- 1993-08-31 MX MX9305294A patent/MX9305294A/es unknown
- 1993-08-31 RU RU93049265A patent/RU2117661C1/ru active
- 1993-08-31 NO NO933100A patent/NO304072B1/no not_active IP Right Cessation
- 1993-08-31 AU AU46003/93A patent/AU656482B2/en not_active Expired
- 1993-09-01 PL PL93300250A patent/PL173809B1/pl unknown
- 1993-09-01 CN CN93117627A patent/CN1043762C/zh not_active Expired - Lifetime
- 1993-09-01 KR KR1019930017398A patent/KR100274367B1/ko not_active IP Right Cessation
- 1993-09-01 JP JP21744193A patent/JP3601840B2/ja not_active Expired - Lifetime
- 1993-09-01 MY MYPI93001753A patent/MY131442A/en unknown
-
1994
- 1994-11-21 US US08/343,079 patent/US5637712A/en not_active Expired - Lifetime
-
1995
- 1995-06-01 US US08/457,766 patent/US5675008A/en not_active Expired - Lifetime
- 1995-06-01 US US08/456,577 patent/US5648492A/en not_active Expired - Lifetime
- 1995-06-01 US US08/456,439 patent/US5670516A/en not_active Expired - Lifetime
- 1995-06-01 US US08/457,556 patent/US5606062A/en not_active Expired - Lifetime
- 1995-06-22 HU HU95P/P00401P patent/HU211992A9/hu unknown
-
1998
- 1998-12-23 HK HK98115176A patent/HK1013989A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUT65228A (en) | Process for producing decahyroisoquinoline-3-carboxylic acid derivatives and pharmaceutical preparations containing them | |
HUT58322A (en) | Process for producing new n-(3-hydroxy-4-piperidinyl)-dihydro-benzofurane-, -dihydro-2h-penzopyrane- and -dihydro-benzodioxine-carboxamide derivatives and pharmaceutical compositions containing them | |
HUT48589A (en) | Process for production of new derivatives of substituated n-/1-hydroxi-4-piperidinil/-benzamid | |
GB8719102D0 (en) | Therapeutic agents | |
HU908014D0 (en) | Process for producing amino-carbonyl-carbamates analogues to physostigmine and pharmaceutical preparatives containing these compounds | |
ATE141606T1 (de) | Cephemverbindungen und verfahren zu ihrer herstellung | |
HU895648D0 (en) | Process for the preparation of n,n-disubstituted diaryl-alkancarboxylic acid amide derivatives and pharmaceutical compositions containing such compounds | |
HUT57211A (en) | Process for producing pyrrolo-pyrimidine derivatives, pharmaceutically acceptable salts thereof and pahrmaceutical compositions containing them as active components | |
ES2052901T3 (es) | Un metodo para preparar derivados e isomeros de 4,5,6,7-tetrahidroisotiazolo(4,5-c)piridinas. | |
HUT45059A (en) | Process for producing abeoergoline derivatives | |
DE69708640D1 (de) | Pyridoncarbonsäure-derivate und zwischenverbindungen für deren herstellung | |
RO112613B1 (ro) | Derivaţi de acid hidroxamic, procedee pentru prepararea acestora, intermediari de sinteză si compoziţie farmaceutică |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HFG4 | Patent granted, date of granting |
Effective date: 20050301 |